May 27, 2026 8:00 am EDT Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 18, 2026 4:05 pm EDT Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
May 06, 2026 4:05 pm EDT Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 05, 2026 5:34 pm EDT Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
May 05, 2026 8:00 am EDT Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
Apr 29, 2026 4:05 pm EDT Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026
Mar 16, 2026 4:05 pm EDT Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Mar 12, 2026 4:05 pm EDT Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
Mar 09, 2026 4:30 pm EDT Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
